• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2020 年 8 月至 2021 年 7 月期间 SARS-CoV-2 变异株的地理流行情况。

Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021.

机构信息

Department of Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong, China.

出版信息

Sci Rep. 2022 Mar 18;12(1):4704. doi: 10.1038/s41598-022-08684-1.

DOI:10.1038/s41598-022-08684-1
PMID:35304553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8931783/
Abstract

We extracted one-year genomic data (August 2020-July 2021) from GISAID EpiCoV™ database and estimated monthly proportions of 11 SARS-CoV-2 variants in various geographical regions. From continental perspective, Delta VOC predominated in Africa, Asia, Europe, North America and Oceania, with proportions of 67.58-98.31% in July 2021. In South America, proportion of Delta VOC (23.24%) has been approaching the predominant yet diminishing Gamma VOC (56.86%). We further analyzed monthly data on new COVID-19 cases, new deaths, vaccination status and variant proportions of 6 countries. Delta VOC predominated in all countries except Brazil (Gamma VOC) in July 2021. In most occasions, rise and predominance of Alpha, Beta, Gamma, Delta and Zeta variants were accompanied with surges of new cases, especially after the time point of major lineage interchange. The ascending phases of new cases lasted for 1-5 months with 1.69- to 40.63-fold peak growth, whereas new death tolls varied with regional vaccination status. Our data suggested surges of COVID-19 cases might be predicted from variant surveillance data. Despite vaccine breakthroughs by Delta VOC, death tolls were more stable in countries with better immunization coverage. Another takeaway is the urgent need to improve vaccine efficacy against Delta and emerging variants.

摘要

我们从 GISAID EpiCoV™ 数据库中提取了一年(2020 年 8 月至 2021 年 7 月)的基因组数据,并估计了不同地理区域中 11 种 SARS-CoV-2 变体的月度比例。从大陆角度来看,Delta VOC 在非洲、亚洲、欧洲、北美和大洋洲占主导地位,2021 年 7 月的比例为 67.58%-98.31%。在南美洲,Delta VOC 的比例(23.24%)已接近占主导地位但逐渐减少的 Gamma VOC(56.86%)。我们进一步分析了 6 个国家的每月新 COVID-19 病例、新死亡、疫苗接种情况和变体比例数据。2021 年 7 月,除巴西(Gamma VOC)外,所有国家均以 Delta VOC 为主导。在大多数情况下,Alpha、Beta、Gamma、Delta 和 Zeta 变体的上升和主导地位伴随着新病例的激增,尤其是在主要谱系交换后。新病例的上升阶段持续了 1-5 个月,峰值增长率为 1.69 至 40.63 倍,而新死亡人数则因地区疫苗接种情况而异。我们的数据表明,新的 COVID-19 病例可能可以通过变体监测数据来预测。尽管 Delta VOC 疫苗突破性感染有所增加,但疫苗接种率较高的国家的死亡人数更为稳定。另一个重要启示是,迫切需要提高针对 Delta 和新兴变体的疫苗效力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e158/8933550/0b71719b796f/41598_2022_8684_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e158/8933550/57aaf20a14e1/41598_2022_8684_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e158/8933550/0b71719b796f/41598_2022_8684_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e158/8933550/57aaf20a14e1/41598_2022_8684_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e158/8933550/0b71719b796f/41598_2022_8684_Fig2_HTML.jpg

相似文献

1
Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021.2020 年 8 月至 2021 年 7 月期间 SARS-CoV-2 变异株的地理流行情况。
Sci Rep. 2022 Mar 18;12(1):4704. doi: 10.1038/s41598-022-08684-1.
2
Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions.Delta 变异株在巴西不同地区的出现和传播
Microbiol Spectr. 2022 Oct 26;10(5):e0264121. doi: 10.1128/spectrum.02641-21. Epub 2022 Aug 24.
3
Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil.巴西圣保罗州疫苗接种示范城市中关注的 SARS-CoV-2 变体的动态。
Viruses. 2022 Sep 29;14(10):2148. doi: 10.3390/v14102148.
4
SARS-CoV-2 Genomic Surveillance in Brazil: A Systematic Review with Scientometric Analysis.巴西的 SARS-CoV-2 基因组监测:系统评价与科学计量分析。
Viruses. 2022 Dec 5;14(12):2715. doi: 10.3390/v14122715.
5
Monitoring the Establishment of VOC Gamma in Minas Gerais, Brazil: A Retrospective Epidemiological and Genomic Surveillance Study.监测巴西米纳斯吉拉斯州 VOC Gamma 的建立:一项回顾性流行病学和基因组监测研究。
Viruses. 2022 Dec 9;14(12):2747. doi: 10.3390/v14122747.
6
Genomic monitoring of the SARS-CoV-2 B1.1.7 (WHO VOC Alpha) in the Sao Paulo state, Brazil.巴西圣保罗州对 SARS-CoV-2 B1.1.7(世界卫生组织 VOC Alpha)的基因组监测。
Virus Res. 2022 Jan 15;308:198643. doi: 10.1016/j.virusres.2021.198643. Epub 2021 Nov 27.
7
Early Emergence and Dispersal of Delta SARS-CoV-2 Lineage AY.99.2 in Brazil.新冠病毒德尔塔变异株AY.99.2在巴西的早期出现与传播
Front Med (Lausanne). 2022 Jun 17;9:930380. doi: 10.3389/fmed.2022.930380. eCollection 2022.
8
Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021.成人因实验室确诊的 COVID-19 住院的严重程度在 SARS-CoV-2 B.1.617.2(Delta)流行之前和期间-COVID-NET,14 个州,2021 年 1 月至 8 月。
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1513-1519. doi: 10.15585/mmwr.mm7043e1.
9
The Divergent Pattern of SARS-CoV-2 Variant Predominance and Transmission Dynamics in the Brazilian Island of Ilhabela.巴西伊利亚贝拉岛 SARS-CoV-2 变异株优势和传播动力学的离散模式。
Viruses. 2022 Jul 5;14(7):1481. doi: 10.3390/v14071481.
10
SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant.SARS-CoV-2 B.1.1.7 衰退并非由更成功的变异株引起。
Microbiol Spectr. 2021 Dec 22;9(3):e0112821. doi: 10.1128/Spectrum.01128-21. Epub 2021 Nov 17.

引用本文的文献

1
The role of inflammatory gene polymorphisms in severe COVID-19: a review.炎症基因多态性在重症新型冠状病毒肺炎中的作用:综述
Virol J. 2024 Dec 20;21(1):327. doi: 10.1186/s12985-024-02597-3.
2
"The COVID-19 pandemic in BRICS: Milestones, interventions, and molecular epidemiology".金砖国家的新冠疫情:里程碑、应对措施及分子流行病学
PLOS Glob Public Health. 2024 Dec 20;4(12):e0003023. doi: 10.1371/journal.pgph.0003023. eCollection 2024.
3
Unveiling pandemic patterns: a detailed analysis of transmission and severity parameters across four COVID-19 waves in Bogotá, Colombia.

本文引用的文献

1
New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.巴西里约热内卢自然感染和接种疫苗后,对 SARS-CoV-2 关注变体的新感染。
Infect Genet Evol. 2021 Oct;94:104998. doi: 10.1016/j.meegid.2021.104998. Epub 2021 Jul 10.
2
An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.2021 年 4 月,在英国伦敦,一家养老院在部分接种了一剂 COVID-19 疫苗 Vaxzevria 后,由 SARS-CoV-2 Delta(B.1.617.2)变异株引发的疫情。
Euro Surveill. 2021 Jul;26(27). doi: 10.2807/1560-7917.ES.2021.26.27.2100626.
3
揭示疫情模式:对哥伦比亚波哥大新冠疫情四波期间传播和严重程度参数的详细分析。
BMC Glob Public Health. 2024 Dec 10;2(1):83. doi: 10.1186/s44263-024-00105-x.
4
SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia.关注的 SARS-CoV-2 变体在原代人呼吸道上皮细胞中的适应性和适应性。
Cell Rep. 2024 Apr 23;43(4):114076. doi: 10.1016/j.celrep.2024.114076. Epub 2024 Apr 10.
5
Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon.对 SARS-CoV-2 的基因组监测显示,德尔塔变体的严重程度和死亡率均高于其他变体:来自喀麦隆的证据。
Sci Rep. 2023 Dec 8;13(1):21654. doi: 10.1038/s41598-023-48773-3.
6
COVID-19 in 16 West African Countries: An Assessment of the Epidemiology and Genetic Diversity of SARS-CoV-2 after Four Epidemic Waves.16 个西非国家的 COVID-19 疫情:四次疫情浪潮后 SARS-CoV-2 的流行病学和遗传多样性评估。
Am J Trop Med Hyg. 2023 Aug 28;109(4):861-873. doi: 10.4269/ajtmh.22-0469. Print 2023 Oct 4.
7
The global dynamic transmissibility of COVID-19 and its influencing factors: an analysis of control measures from 176 countries.COVID-19 的全球动态传播力及其影响因素:来自 176 个国家的控制措施分析。
BMC Public Health. 2023 Feb 28;23(1):404. doi: 10.1186/s12889-023-15174-0.
8
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.新型冠状病毒肺炎疫苗在自身免疫性疾病患者、有心脏问题的患者及健康人群中的安全性
Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233.
9
Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.儿童咽淋巴组织中存在针对 SARS-CoV-2 的适应性免疫应答。
Nat Immunol. 2023 Jan;24(1):186-199. doi: 10.1038/s41590-022-01367-z. Epub 2022 Dec 19.
COVID-19 in fully vaccinated Everest trekkers in Nepal.
尼泊尔完全接种疫苗的珠穆朗玛峰徒步旅行者中的 COVID-19 病例。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab098.
4
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.一项观察性队列研究,评估了抗体和疫苗接种状态对医护人员严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染和 B.1.1.7 变异株感染发生率的影响。
Clin Infect Dis. 2022 Apr 9;74(7):1208-1219. doi: 10.1093/cid/ciab608.
5
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.医护人员接种 Comirnaty(BNT162b2,辉瑞/ BioNTech)后对 Delta(B.1.617.2)和其他关注变种的中和能力,以色列。
Euro Surveill. 2021 Jul;26(26). doi: 10.2807/1560-7917.ES.2021.26.26.2100557.
6
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.巴西科兴新冠疫苗接种者中两例接种后感染 P1 变异株的 SARS-CoV-2 病例研究。
Viruses. 2021 Jun 26;13(7):1237. doi: 10.3390/v13071237.
7
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.苏格兰的新冠病毒德尔塔变异株:人口统计学、住院风险及疫苗有效性
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
8
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.关于使用严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体结合域作为预防性疫苗靶点的分子层面问题。
ACS Cent Sci. 2021 May 26;7(5):757-767. doi: 10.1021/acscentsci.1c00216. Epub 2021 Apr 19.
9
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.科兴新冠疫苗诱导产生的针对新冠病毒变异株的血清中和活性。
Lancet Infect Dis. 2021 Aug;21(8):1071-1072. doi: 10.1016/S1473-3099(21)00287-5. Epub 2021 May 27.
10
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.体液免疫应答对循环 SARS-CoV-2 变体引发的灭活和 RBD-亚单位疫苗。
Cell Res. 2021 Jul;31(7):732-741. doi: 10.1038/s41422-021-00514-9. Epub 2021 May 21.